Wendy K Adams1, Chris Barkus1,2, Jacqueline-Marie N Ferland1, Trevor Sharp2, Catharine A Winstanley3. 1. Department of Psychology, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 2215 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada. 2. Department of Pharmacology, University of Oxford, Oxford, UK. 3. Department of Psychology, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 2215 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada. cwinstanley@psych.ubc.ca.
Abstract
RATIONALE: Adding reward-concurrent cues to a rat gambling task (rGT) increases risky choice. This cued version of the task may reflect an "addiction-like" cognitive process, more similar to human gambling than the uncued task. Serotonergic drugs that target 5-HT2 receptors alter mechanisms linked to impulse control. However, relatively little is known regarding the impact of such agents on either risky decision making, or the ability of conditioned stimuli to bias the choice process, despite potential relevance to addiction development and treatment. OBJECTIVES: The aim of this study was to determine the effects of SB 242,084 and M100907, selective antagonists at the 5-HT2C and 5-HT2A receptors respectively, as well as the selective 5-HT2C receptor agonist Ro-60-0175, on performance of both cued and uncued versions of the rGT. RESULTS: SB 242,084 significantly and dose-dependently increased choice of the most optimal option in the cued rGT only, despite concurrently increasing impulsive responses made prematurely on both the cued and uncued rGT. M100907 and Ro-60-0175 did not alter risky decision making, but nevertheless produced the expected decrease in premature responses on both task variants. CONCLUSIONS: These findings demonstrate that the 5-HT2 receptor-mediated regulation of risky decision making and motor impulsivity can be pharmacologically dissociated and further show that the presence of highly salient reward-paired cues critically alters the neurochemical regulation of the choice process. Importantly, these results suggest that 5-HT2C receptor antagonists may be of use in disrupting maladaptive patterns of decision making.
RATIONALE: Adding reward-concurrent cues to a rat gambling task (rGT) increases risky choice. This cued version of the task may reflect an "addiction-like" cognitive process, more similar to human gambling than the uncued task. Serotonergic drugs that target 5-HT2 receptors alter mechanisms linked to impulse control. However, relatively little is known regarding the impact of such agents on either risky decision making, or the ability of conditioned stimuli to bias the choice process, despite potential relevance to addiction development and treatment. OBJECTIVES: The aim of this study was to determine the effects of SB 242,084 and M100907, selective antagonists at the 5-HT2C and 5-HT2A receptors respectively, as well as the selective 5-HT2C receptor agonist Ro-60-0175, on performance of both cued and uncued versions of the rGT. RESULTS:SB 242,084 significantly and dose-dependently increased choice of the most optimal option in the cued rGT only, despite concurrently increasing impulsive responses made prematurely on both the cued and uncued rGT. M100907 and Ro-60-0175 did not alter risky decision making, but nevertheless produced the expected decrease in premature responses on both task variants. CONCLUSIONS: These findings demonstrate that the 5-HT2 receptor-mediated regulation of risky decision making and motor impulsivity can be pharmacologically dissociated and further show that the presence of highly salient reward-paired cues critically alters the neurochemical regulation of the choice process. Importantly, these results suggest that 5-HT2C receptor antagonists may be of use in disrupting maladaptive patterns of decision making.
Authors: Latham H L Fink; Noelle C Anastasio; Robert G Fox; Kenner C Rice; F Gerard Moeller; Kathryn A Cunningham Journal: Neuropsychopharmacology Date: 2015-02-10 Impact factor: 7.853
Authors: J R Martin; M Bös; F Jenck; J Moreau; V Mutel; A J Sleight; J Wichmann; J S Andrews; H H Berendsen; C L Broekkamp; G S Ruigt; C Köhler; A M Delft Journal: J Pharmacol Exp Ther Date: 1998-08 Impact factor: 4.030
Authors: Noelle C Anastasio; Sonja J Stutz; Robert G Fox; Robert M Sears; Ronald B Emeson; Ralph J DiLeone; Richard T O'Neil; Latham H Fink; Dingge Li; Thomas A Green; F Gerard Moeller; Kathryn A Cunningham Journal: Neuropsychopharmacology Date: 2013-08-13 Impact factor: 7.853
Authors: Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt Journal: Lancet Psychiatry Date: 2016-05-17 Impact factor: 27.083
Authors: Robin L Carhart-Harris; Suresh Muthukumaraswamy; Leor Roseman; Mendel Kaelen; Wouter Droog; Kevin Murphy; Enzo Tagliazucchi; Eduardo E Schenberg; Timothy Nest; Csaba Orban; Robert Leech; Luke T Williams; Tim M Williams; Mark Bolstridge; Ben Sessa; John McGonigle; Martin I Sereno; David Nichols; Peter J Hellyer; Peter Hobden; John Evans; Krish D Singh; Richard G Wise; H Valerie Curran; Amanda Feilding; David J Nutt Journal: Proc Natl Acad Sci U S A Date: 2016-04-11 Impact factor: 12.779
Authors: Shelby L Blaes; Caitlin A Orsini; Marci R Mitchell; Megan S Spurrell; Sara M Betzhold; Kenneth Vera; Jennifer L Bizon; Barry Setlow Journal: Behav Pharmacol Date: 2018-12 Impact factor: 2.293
Authors: Jacqueline-Marie N Ferland; Tristan J Hynes; Celine D Hounjet; David Lindenbach; Cole Vonder Haar; Wendy K Adams; Anthony G Phillips; Catharine A Winstanley Journal: J Neurosci Date: 2019-01-09 Impact factor: 6.167
Authors: Angela J Langdon; Brett A Hathaway; Samuel Zorowitz; Cailean B W Harris; Catharine A Winstanley Journal: Psychopharmacology (Berl) Date: 2019-06-29 Impact factor: 4.530
Authors: Oliver Härmson; Laura L Grima; Marios C Panayi; Masud Husain; Mark E Walton Journal: Psychopharmacology (Berl) Date: 2021-11-11 Impact factor: 4.530